open access

Vol 91, No 3 (2020)
ORIGINAL PAPERS Obstetrics
Published online: 2020-03-31
Get Citation

Quantitative and qualitative Ductus Venosus blood flow evaluation in the screening for Trisomy 18 and 13 — suitability study

Bartosz Czuba, Malgorzata Nycz-Reska, Wojciech Cnota, Agnieszka Jagielska, Agata Wloch, Dariusz Borowski, Piotr Wegrzyn
DOI: 10.5603/GP.2020.0031
·
Pubmed: 32266955
·
Ginekol Pol 2020;91(3):144-148.

open access

Vol 91, No 3 (2020)
ORIGINAL PAPERS Obstetrics
Published online: 2020-03-31

Abstract

Objectives: The objective of the paper is the suitability assessment of screening for Trisomy 18 and 13 on the basis of
nuchal translucency (NT) measurement, Fetal Heart Rate (FHR), double test, quantitative [Ductus Venosus (DV) Pulsatility
Index for Veins (PIV)] and qualitative (the A-wave assessment) blood flow evaluation in the DV.
Material and methods: The study was performed in 7296 singleton pregnancies. In each fetus NT, FHR, DV-PIV were
examined. Double test from maternal blood was examined. These ultrasound and biochemical factors were in combined
screening investigated. Additional doppler ultrasound markers such as abnormal a-wave in Ductus Venosus and Pusatility
Index for Veins of Ductus Venosus were and their impact on Trisomies 18 and 13 screening were examined.
Results: Two groups of patients were compared — with chromosomal normal and chromosomal abnormalities — Trisomy
18 and 13. Detection Rate of Trisomies 18 and 13 at the risk cutoff 1/300 using combined screening was 90.2% and FPR was
6%. Detection Rates of examined chromosomal abnormalities using contingent screening were: 92.1% using DV abnormal
a-wave and 94.84% using DV-PIV. FPR’s for booths parameters 5.8% and 5.4% respectively.
Conclusions: Quantitative analysis of the flow — assessment of DV-PIV in the first trimester significantly influences the
improvement of screening values focusing on Trisomy 18 and 13 detection.

Abstract

Objectives: The objective of the paper is the suitability assessment of screening for Trisomy 18 and 13 on the basis of
nuchal translucency (NT) measurement, Fetal Heart Rate (FHR), double test, quantitative [Ductus Venosus (DV) Pulsatility
Index for Veins (PIV)] and qualitative (the A-wave assessment) blood flow evaluation in the DV.
Material and methods: The study was performed in 7296 singleton pregnancies. In each fetus NT, FHR, DV-PIV were
examined. Double test from maternal blood was examined. These ultrasound and biochemical factors were in combined
screening investigated. Additional doppler ultrasound markers such as abnormal a-wave in Ductus Venosus and Pusatility
Index for Veins of Ductus Venosus were and their impact on Trisomies 18 and 13 screening were examined.
Results: Two groups of patients were compared — with chromosomal normal and chromosomal abnormalities — Trisomy
18 and 13. Detection Rate of Trisomies 18 and 13 at the risk cutoff 1/300 using combined screening was 90.2% and FPR was
6%. Detection Rates of examined chromosomal abnormalities using contingent screening were: 92.1% using DV abnormal
a-wave and 94.84% using DV-PIV. FPR’s for booths parameters 5.8% and 5.4% respectively.
Conclusions: Quantitative analysis of the flow — assessment of DV-PIV in the first trimester significantly influences the
improvement of screening values focusing on Trisomy 18 and 13 detection.

Get Citation

Keywords

Combined test trisomy 18 trisomy 13; first trimester nuchal translucency thickness; ductus venosus pulsatility index for veins; serum free β-hcg; pregnancy-associated plasma protein A

About this article
Title

Quantitative and qualitative Ductus Venosus blood flow evaluation in the screening for Trisomy 18 and 13 — suitability study

Journal

Ginekologia Polska

Issue

Vol 91, No 3 (2020)

Pages

144-148

Published online

2020-03-31

DOI

10.5603/GP.2020.0031

Pubmed

32266955

Bibliographic record

Ginekol Pol 2020;91(3):144-148.

Keywords

Combined test trisomy 18 trisomy 13
first trimester nuchal translucency thickness
ductus venosus pulsatility index for veins
serum free β-hcg
pregnancy-associated plasma protein A

Authors

Bartosz Czuba
Malgorzata Nycz-Reska
Wojciech Cnota
Agnieszka Jagielska
Agata Wloch
Dariusz Borowski
Piotr Wegrzyn

References (15)
  1. Khoshnood B, de Vigan C, Vodovar V, et al. Trends in prenatal diagnosis, pregnancy termination, and perinatal mortality of newborns with congenital heart disease in France, 1983-2000: a population-based evaluation. Pediatrics. . 2005; 115(1): 95–101.
  2. Becker R, Wegner RD. Detailed screening for fetal anomalies and cardiac defects at the 11-13-week scan. Ultrasound Obstet Gynecol. 2006; 27(6): 613–618.
  3. Maiz N, Valencia C, Kagan KO, et al. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009; 33(5): 512–517.
  4. Borrell A, Grande M, Bennasar M, et al. First-trimester detection of major cardiac defects with the use of ductus venosus blood flow. Ultrasound Obstet Gynecol. 2013; 42(1): 51–57.
  5. Nicolaides KH, Syngelaki A, Poon LC, et al. First-trimester contingent screening for trisomy 21 by biomarkers and maternal blood cell-free DNA testing. Ultrasound Obstet Gynecol. 2013; 42(1): 41–50.
  6. Jaczyńska R, Borowski D, Czuba B, et al. [PI index value in fetal ductus venosus blood flow at 11-14 weeks in normal course of pregnancy]. Ginekol Pol. 2006; 77(5): 345–351.
  7. Maiz N, Valencia C, Kagan KO, et al. Ductus venosus Doppler in screening for trisomies 21, 18 and 13 and Turner syndrome at 11-13 weeks of gestation. Ultrasound Obstet Gynecol. 2009; 33(5): 512–517.
  8. Maiz N, Nicolaides KH. Ductus venosus in the first trimester: contribution to screening of chromosomal, cardiac defects and monochorionic twin complications. Fetal Diagn Ther. 2010; 28(2): 65–71.
  9. Pietryga M, Borowski D, Brązert J, et al. Polish Gynecological Society. Polish Gynecological Society – Ultrasound Section Guidelines on ultrasound screening in gynecology – 2015. Polish Gynaecology. 2015; 86(8): 635–639.
  10. Nicolaides K, Węgrzyn P. Badanie ultrasongraficzne pomiędzy110-13+6tygodniem ciąży. Fetal Medicine Foundation, London 2004.
  11. Baś-Budecka E, Perenc M, Sieroszewski P. Ocena przezierności karkowej (NT) oraz spektrum przepływu w przewodzie żylnym (DV) w wykrywaniu wad serca płodu. Ginekol Pol. 2010; 81: 272–276.
  12. Maiz N, Plasencia W, Dagklis T, et al. Ductus venosus Doppler in fetuses with cardiac defects and increased nuchal translucency thickness. Ultrasound Obstet Gynecol. 2008; 31(3): 256–260.
  13. Wright D, Syngelaki A, Bradbury I, et al. First-trimester screening for trisomies 21, 18 and 13 by ultrasound and biochemical testing. Fetal Diagn Ther. 2014; 35(2): 118–126.
  14. Kagan KO, Wright D, Valencia C, et al. Screening for trisomies 21, 18 and 13 by maternal age, fetal nuchal translucency, fetal heart rate, free beta-hCG and pregnancy-associated plasma protein-A. Hum Reprod. 2008; 23(9): 1968–1975.
  15. Florjański J, Fuchs T, Zimmer M, et al. The role of ductus venosus Doppler flow in the diagnosis of chromosomal abnormalities during the first trimester of pregnancy. Adv Clin Exp Med. 2013; 22(3): 395–401.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl